Wednesday - July 9, 2025
Goodwin Guides Kymera Therapeutics in $750 Million Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders with Gilead Sciences
July 08, 2025
BOSTON, Massachusetts, July 8 [Category: BizLaw/Legal] -- Goodwin, a law firm, issued the following news release:

* * *

Goodwin Guides Kymera Therapeutics in $750 Million Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders with Gilead Sciences

*

The Life Sciences team guided Kymera Therapeutics, Inc. on entering into an exclusive option and license agreement to accelerate the development and commercializat . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products